News
DXCM
69.62
+0.27%
0.19
Looking Into DexCom's Recent Short Interest
Benzinga · 18h ago
Down More Than 50% From Its High, Is DexCom Stock a Buy?
The Motley Fool · 1d ago
Labaton Keller Sucharow LLP Announces Expanded Securities Class Action Lawsuit Filed Against DexCom, Inc. and Certain Executives
Barchart · 1d ago
DexCom Price Target Cut to $120.00/Share From $130.00 by RBC Capital
Dow Jones · 1d ago
DexCom Is Maintained at Outperform by RBC Capital
Dow Jones · 1d ago
RBC Capital Maintains Outperform on DexCom, Lowers Price Target to $120
Benzinga · 1d ago
DexCom price target lowered to $120 from $130 at RBC Capital
TipRanks · 1d ago
October 2024 US Stocks That May Be Trading Below Estimated Value
Simply Wall St · 1d ago
DexCom Stock Remains a “Strong Buy” Despite Fierce Competition
TipRanks · 1d ago
Weekly Report: what happened at DXCM last week (0930-1004)?
Weekly Report · 3d ago
Here's What to Expect From DexCom's Next Earnings Report
Barchart · 3d ago
DXCM Quantitative Stock Analysis
NASDAQ · 4d ago
2 Beaten-Down Growth Stocks You Might Regret Not Buying
The Motley Fool · 4d ago
Is DexCom a Millionaire Maker?
The Motley Fool · 5d ago
DexCom put volume heavy and directionally bearish
TipRanks · 5d ago
ResMed Stock Is Surging. Expect More Gains for the Medical Equipment Maker.
Barron‘s · 10/03 06:00
Bristol-Myers tops growth chart among S&P 500 healthcare stocks in Q3
Seeking Alpha · 10/02 14:07
Reasons to Retain DexCom Stock in Your Portfolio for Now
NASDAQ · 10/02 12:32
Down More Than 50%, Is DexCom Stock a Bargain Now?
The Motley Fool · 10/02 08:11
VOO ETF Update, 10/2/2024  
NASDAQ · 10/02 02:08
More
Webull provides a variety of real-time DXCM stock news. You can receive the latest news about Dexcom Inc through multiple platforms. This information may help you make smarter investment decisions.
About DXCM
DexCom, Inc. is a medical device company. The Company enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The Company is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The Company is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device.